A novel anti‐HIV‐1 bispecific bNAb‐lectin fusion protein engineered in a plant‐based transient expression system

The discovery of broadly neutralizing antibodies (bNAbs) has been a major step towards better prophylactic and therapeutic agents against human immunodeficiency virus type 1 (HIV‐1). However, effective therapy will likely require a combination of anti‐HIV agents to avoid viral evasion. One possible...

Descripción completa

Detalles Bibliográficos
Autores principales: Seber Kasinger, Lauren E., Dent, Matthew W., Mahajan, Garima, Hamorsky, Krystal Teasley, Matoba, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662308/
https://www.ncbi.nlm.nih.gov/pubmed/30729651
http://dx.doi.org/10.1111/pbi.13090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662308/
https://www.ncbi.nlm.nih.gov/pubmed/30729651
http://dx.doi.org/10.1111/pbi.13090

Ejemplares similares